Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 7, 2005, Pages 2983-2985

  Parikh, Sunil ^a,c   Gut, Jiri ^a   Istvan, Eva ^b   Goldberg, Daniel E ^b   Havlir, Diane V ^a   Rosenthal, Philip J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIMALARIAL AGENT; ASPARTIC PROTEINASE; ATAZANAVIR; CYTOCHROME P450; DIMETHYL SULFOXIDE; INDINAVIR; LOPINAVIR; NELFINAVIR; PLASMEPSIN II; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ERYTHROCYTE; FLUORESCENCE ACTIVATED CELL SORTER; GIEMSA STAIN; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROLYSIS; IC 50; IN VITRO STUDY; MICROSCOPY; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; ASPARTIC ENDOPEPTIDASES; CULTURE MEDIA; HIV PROTEASE INHIBITORS; HUMANS; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM;

EID: 21444431504     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.7.2983-2985.2005     Document Type: Article

References (15)

1. Bailly, E., R. Jambou, J. Savel, and G. Jaureguiberry. 1992. Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and pepstatin A (aspartyl protease inhibitor). J. Protozool. 39:593-599.
2. Banerjee, R., J. Liu, W. Beatty, L. Pelosof, M. Klemba, and D. E. Goldberg. 2002. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. Natl. Acad. Sci. USA 99:990-995.
3. Boffito, M., S. Bonora, R. Raiteri, H. E. Reynolds, P. G. Hoggard, A. Sinicco, D. J. Back, and G. Di Perri. 2002. Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting. Ther. Drug Monit. 24:574-576.
4. Cooper, C. L., R. P. van Heeswijk, K. Gallicano, and D. W. Cameron. 2003. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin. Infect. Dis. 36:1585-1592.
5. Corbett, E. L., R. W. Steketee, F. O. ter Kuile, A. S. Latif, A. Kamali, and R. J. Hayes. 2002. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 359:2177-2187.
6. Dash, C., A. Kulkarni, B. Dunn, and M. Rao. 2003. Aspartic peptidase inhibitors: implications in drug development. Crit. Rev. Biochem. Mol. Biol. 38:89-119.
7. Goujard, C., I. Vincent, J. L. Meynard, N. Choudet, D. Bollens, C. Rousseau, D. Demarles, C. Gillotin, R. Bidault, and A. M. Taburet. 2003. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 47:118-123.
8. King, J. R., R. Yogev, G. Aldrovandi, E. Chadwick, and E. P. Acosta. 2004. Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube. HIV Clin. Trials 5:288-293.
9. Nathoo, S., L. Serghides, and K. C. Kain. 2003. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet 362:1039-1041.
10. Rosenthal, P. J. 1995. Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. Exp. Parasitol. 80:272-281.
11. Sijwali, P. S., and P. J. Rosenthal. 2004. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 101:4384-4389.
12. Singh, A., and P. J. Rosenthal. 2001. Comparison of efficacies of cysteine protease inhibitors against five strains of Plasmodium falciparum. Antimicrob. Agents Chemother. 45:949-951.
13. Skinner-Adams, T. S., J. S. McCarthy, D. L. Gardiner, P. M. Hilton, and K. T. Andrews. 2004. Antiretrovirals as antimalarial agents. J. Infect. Dis. 190:1998-2000.
14. Veldkamp, A. I., R. P. van Heeswijk, J. W. Mulder, P. L. Meenhorst, G. Schreij, S. van der Geest, J. M. Lange, J. H. Beijnen, and R. M. Hoetelmans. 2001. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 27:344-349.
15. World Health Organization. 30 November 2003, posting date. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003 revision. World Health Organization, Geneva, Switzerland. [Online.] http://www.who.int/3by5/publications/documents/ arv_guidelines/en/.